Assembly Bio reports Phase 1a safety and target-engagement results for ABI-6250
Assembly Biosciences said its Phase 1a trial of oral NTCP inhibitor ABI-6250 in healthy participants found the drug was tolerated, with no serious adverse events, and produced reversible bile-acid increases consistent with target engagement. The company will present the findings in two posters at the AASLD Liver Meeting in Denver. Assembly Bio said it plans to begin Phase 2 work in chronic HDV and cholestatic liver diseases in subsequent periods.
Why it matters
The Phase 1a findings provide safety and pharmacodynamic support for Assembly Bio's stated plan to advance ABI-6250 into Phase 2 studies. The reported study was in healthy participants, so patient efficacy data were not provided.
Key facts
- 1Assembly Biosciences said ABI-6250 had no serious adverse events in its randomized, blinded Phase 1a study of healthy participants. globenewswire.com
- 2The company reported dose-related and reversible increases in total and conjugated bile acids, which it said were consistent with NTCP engagement. globenewswire.com
- 3Assembly Biosciences plans to start a chronic HDV Phase 2 study in the fourth quarter of 2026. globenewswire.com
- 4The company plans a Phase 2 study in cholestatic liver diseases in the first quarter of 2027. globenewswire.com
- 5Assembly Biosciences will show two ABI-6250 posters at the AASLD meeting in Denver from November 5-9, 2026. globenewswire.com
Open questions
- The materials do not report patient efficacy results for ABI-6250, as the Phase 1a study involved healthy participants.
Summary written by AlphAI from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.